BAYER AKTIENGESELLSCHAFT 4
4 · Century Therapeutics, Inc. · Filed Jun 23, 2021
Insider Transaction Report
Form 4
BAYER AKTIENGESELLSCHAFT
10% Owner
Transactions
- Conversion
Common Stock
2021-06-22+1,535,238→ 11,925,838 total - Conversion
Series B Preferred Stock
2021-06-22−26,143,790→ 0 total→ Common Stock (10,390,600 underlying) - Conversion
Common Stock
2021-06-22+10,390,600→ 10,390,600 total - Purchase
Common Stock
2021-06-22$20.00/sh+750,000$15,000,000→ 12,675,838 total - Conversion
Series C Preferred Stock
2021-06-22−3,862,813→ 0 total→ Common Stock (1,535,238 underlying)
Footnotes (3)
- [F1]Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.
- [F2]The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
- [F3]Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.